Anti‐tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis | Zendy

Hull D. N. | Zendy; Williams R. O. | Zendy; Pathan E. | Zendy; Alzabin S. | Zendy; Abraham S. | Zendy; Taylor P. C. | Zendy

Open Access

Anti‐tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis

Author(s) -

Hull D. N.,

Williams R. O.,

Pathan E.,

Alzabin S.,

Abraham S.,

Taylor P. C.

Publication year - 2015

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/cei.12626

Subject(s) - elispot , ankylosing spondylitis , psoriatic arthritis , medicine , rheumatoid arthritis , peripheral blood mononuclear cell , tumor necrosis factor alpha , flow cytometry , immunology , arthritis , psoriasis , interleukin 17 , cytokine , t cell , biology , immune system , biochemistry , in vitro

Summary We investigated changes in circulating T helper type 17 (Th17) cells following anti‐tumour necrosis factor (TNF) in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients. Peripheral blood mononuclear cells (PBMC) were isolated from 25 RA, 15 AS and eight PsA patients at baseline 4 and 12 weeks after treatment, and Th17 cell frequencies were analysed using interleukin (IL)‐17 enzyme‐linked immunospot (ELISPOT) and flow cytometry. A significant increase in IL‐17‐producing cells was observed by ELISPOT in RA and AS patients at 12 weeks. Flow cytometry confirmed significant increases in CD4 + IL‐17 + cells at 12 weeks in RA and AS and 4 weeks in PsA patients. Anti‐TNF treatment increases circulating Th17 cells in three different diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research